Related Experiment Video

Updated: Oct 6, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

A Prognostic Merit of Statins in Patients with Chronic Hemodialysis after Percutaneous Coronary Intervention-A

Takehiro Funamizu1, Hiroshi Iwata1, Yuichi Chikata1

  • 1Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.

Journal of Clinical Medicine
|January 21, 2022
PubMed

Insights

Statins reduce cardiovascular death and adverse events in patients with end-stage renal disease (ESRD) undergoing percutaneous coronary intervention (PCI). This study highlights the prognostic benefit of statin therapy in this high-risk population.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Patients with end-stage renal disease (ESRD) on chronic hemodialysis and coronary artery disease (CAD) face high cardiovascular (CV) event and mortality risks.
  • The established CV benefits of statins in the general population remain debated in ESRD patients undergoing PCI.

Purpose of the Study:

  • To investigate the prognostic impact of statin use in ESRD patients with CAD undergoing their first percutaneous coronary intervention (PCI).

Main Methods:

  • A prospective single-center study included 201 ESRD patients on chronic hemodialysis who underwent first-time PCI between 2000 and 2016.
  • Patients were stratified by statin use and by LDL-C levels (median 93 mg/dL) at PCI.
  • Primary endpoint was CV death; secondary endpoints included all-cause death, non-CV death, and 3P-MACE (CV death, MI, stroke).

Main Results:

  • Kaplan-Meier analysis revealed significantly lower cumulative incidences of CV death, all-cause death, and 3P-MACE in patients receiving statins.
  • Multivariate Cox analysis identified statin use as an independent predictor of reduced risk for CV death (HR 0.43), all-cause death (HR 0.50), and 3P-MACE (HR 0.50).
  • No significant difference in outcomes was observed based on LDL-C levels at the time of PCI.

Conclusions:

  • Statin therapy is associated with a reduced risk of adverse cardiovascular outcomes in patients with ESRD following PCI.
  • These findings support the use of statins in ESRD patients with CAD undergoing PCI to improve prognosis.
Abstract

Keywords:
cardiovascular deathhemodialysispercutaneous coronary interventionsecondary preventionstatin

More Related Videos

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
932
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
57
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
59
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
96
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
38
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
170